JP2019536783A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019536783A5 JP2019536783A5 JP2019528632A JP2019528632A JP2019536783A5 JP 2019536783 A5 JP2019536783 A5 JP 2019536783A5 JP 2019528632 A JP2019528632 A JP 2019528632A JP 2019528632 A JP2019528632 A JP 2019528632A JP 2019536783 A5 JP2019536783 A5 JP 2019536783A5
- Authority
- JP
- Japan
- Prior art keywords
- tyrosine
- methyl
- cancer
- composition according
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003112 inhibitor Substances 0.000 claims 12
- 230000002401 inhibitory effect Effects 0.000 claims 12
- 102000031061 Tyrosine 3-monooxygenases Human genes 0.000 claims 10
- 108091000118 Tyrosine 3-monooxygenases Proteins 0.000 claims 10
- 239000002246 antineoplastic agent Substances 0.000 claims 10
- -1 2-chloro-6-fluorobenzyl Chemical group 0.000 claims 8
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- YBBLVLTVTVSKRW-UHFFFAOYSA-N Anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims 3
- NHTGHBARYWONDQ-UHFFFAOYSA-N D,L-α-methyl-Tyrosine Chemical compound OC(=O)C(N)(C)CC1=CC=C(O)C=C1 NHTGHBARYWONDQ-UHFFFAOYSA-N 0.000 claims 3
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 claims 3
- 229960004528 Vincristine Drugs 0.000 claims 3
- 229960002932 anastrozole Drugs 0.000 claims 3
- 229940079593 drugs Drugs 0.000 claims 3
- VXYFARNRGZWHTJ-SBSPUUFOSA-N hydron;methyl (2R)-2-amino-3-(4-hydroxyphenyl)propanoate;chloride Chemical compound Cl.COC(=O)[C@H](N)CC1=CC=C(O)C=C1 VXYFARNRGZWHTJ-SBSPUUFOSA-N 0.000 claims 3
- 150000003667 tyrosine derivatives Chemical group 0.000 claims 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 3
- OMJKFYKNWZZKTK-POHAHGRESA-N (5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1/N=CN=C1C(N)=O OMJKFYKNWZZKTK-POHAHGRESA-N 0.000 claims 2
- VWUXBMIQPBEWFH-WCCTWKNTSA-N (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims 2
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims 2
- 229960002258 Fulvestrant Drugs 0.000 claims 2
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims 2
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 2
- 229960003473 androstanolone Drugs 0.000 claims 2
- 210000004027 cells Anatomy 0.000 claims 2
- 229960003901 dacarbazine Drugs 0.000 claims 2
- 229960002448 dasatinib Drugs 0.000 claims 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 229960003931 peginterferon alfa-2b Drugs 0.000 claims 2
- 108010092851 peginterferon alfa-2b Proteins 0.000 claims 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims 2
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 claims 1
- OOTFAHIVGAQXOL-LBPRGKRZSA-N (2,5-dioxopyrrolidin-1-yl) (2S)-3-(4-hydroxy-3,5-diiodophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound C([C@H](NC(=O)OC(C)(C)C)C(=O)ON1C(CCC1=O)=O)C1=CC(I)=C(O)C(I)=C1 OOTFAHIVGAQXOL-LBPRGKRZSA-N 0.000 claims 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N (2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 claims 1
- JZUZJVFERQWLNC-UHFFFAOYSA-N 2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-(4-hydroxy-3-nitrophenyl)propanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)NC(C(=O)O)CC1=CC=C(O)C([N+]([O-])=O)=C1 JZUZJVFERQWLNC-UHFFFAOYSA-N 0.000 claims 1
- JZKXXXDKRQWDET-UHFFFAOYSA-N 2-azaniumyl-3-(3-hydroxyphenyl)propanoate Chemical compound OC(=O)C(N)CC1=CC=CC(O)=C1 JZKXXXDKRQWDET-UHFFFAOYSA-N 0.000 claims 1
- WWYDYZMNFQIYPT-UHFFFAOYSA-L 2-phenylpropanedioate Chemical compound [O-]C(=O)C(C([O-])=O)C1=CC=CC=C1 WWYDYZMNFQIYPT-UHFFFAOYSA-L 0.000 claims 1
- ACWBBAGYTKWBCD-ZETCQYMHSA-N 3-chloro-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(Cl)=C1 ACWBBAGYTKWBCD-ZETCQYMHSA-N 0.000 claims 1
- QQHMKNYGKVVGCZ-UHFFFAOYSA-N 5-Chloro-6-[(2-Iminopyrrolidin-1-Yl)Methyl]Pyrimidine-2,4(1h,3h)-Dione Chemical compound N1C(=O)NC(=O)C(Cl)=C1CN1C(=N)CCC1 QQHMKNYGKVVGCZ-UHFFFAOYSA-N 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 1
- 229940100198 ALKYLATING AGENTS Drugs 0.000 claims 1
- 229940034982 ANTINEOPLASTIC AGENTS Drugs 0.000 claims 1
- 229960003272 ASPARAGINASE Drugs 0.000 claims 1
- 229960004373 Acetylcholine Drugs 0.000 claims 1
- 229960001686 Afatinib Drugs 0.000 claims 1
- 108010090838 Alemtuzumab Proteins 0.000 claims 1
- 206010059512 Apoptosis Diseases 0.000 claims 1
- ATALOFNDEOCMKK-OITMNORJSA-N Aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 claims 1
- 229940046844 Aromatase inhibitors Drugs 0.000 claims 1
- 102000015790 Asparaginase Human genes 0.000 claims 1
- 108010024976 Asparaginase Proteins 0.000 claims 1
- 229960002756 Azacitidine Drugs 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 229960001561 Bleomycin Drugs 0.000 claims 1
- 108010006654 Bleomycin Proteins 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000006990 Cholangiocarcinoma Diseases 0.000 claims 1
- WDDPHFBMKLOVOX-AYQXTPAHSA-N Clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 claims 1
- 229960002271 Cobimetinib Drugs 0.000 claims 1
- BSMCAPRUBJMWDF-KRWDZBQOSA-N Cobimetinib Chemical compound C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F BSMCAPRUBJMWDF-KRWDZBQOSA-N 0.000 claims 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N Crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 claims 1
- 229960004397 Cyclophosphamide Drugs 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- BFSMGDJOXZAERB-UHFFFAOYSA-N Dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims 1
- 229960000640 Dactinomycin Drugs 0.000 claims 1
- 108010092160 Dactinomycin Proteins 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960003957 Dexamethasone Drugs 0.000 claims 1
- 229960000605 Dexrazoxane Drugs 0.000 claims 1
- BMKDZUISNHGIBY-ZETCQYMHSA-N Dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 229960004679 Doxorubicin Drugs 0.000 claims 1
- 229960001904 EPIRUBICIN Drugs 0.000 claims 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N EPIRUBICIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
- 241000588698 Erwinia Species 0.000 claims 1
- 229960002949 Fluorouracil Drugs 0.000 claims 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N Flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 claims 1
- 206010017758 Gastric cancer Diseases 0.000 claims 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N Gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 108010091266 Gemtuzumab Proteins 0.000 claims 1
- 229960003297 Gemtuzumab ozogamicin Drugs 0.000 claims 1
- 210000004907 Glands Anatomy 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010020243 Hodgkin's disease Diseases 0.000 claims 1
- 201000006743 Hodgkin's lymphoma Diseases 0.000 claims 1
- 102100008763 IFNA2 Human genes 0.000 claims 1
- 229960000908 Idarubicin Drugs 0.000 claims 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 1
- 229960001101 Ifosfamide Drugs 0.000 claims 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N Imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 108010079944 Interferon-alpha2b Proteins 0.000 claims 1
- 108010089187 Ipilimumab Proteins 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 229960003648 Ixazomib Drugs 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- NHTGHBARYWONDQ-JTQLQIEISA-N L-α-methyl-Tyrosine Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C=C1 NHTGHBARYWONDQ-JTQLQIEISA-N 0.000 claims 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 claims 1
- 239000002137 L01XE24 - Ponatinib Substances 0.000 claims 1
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N Lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- 206010024324 Leukaemias Diseases 0.000 claims 1
- 229940008250 Leuprolide Drugs 0.000 claims 1
- 108010000817 Leuprolide Proteins 0.000 claims 1
- 229960004338 Leuprorelin Drugs 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- ANZJBCHSOXCCRQ-UHFFFAOYSA-N Mertansine Chemical compound CN1C(=O)CC(OC(=O)C(C)N(C)C(=O)CCS)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)C=CC=C(C)CC2=CC(OC)=C(Cl)C1=C2 ANZJBCHSOXCCRQ-UHFFFAOYSA-N 0.000 claims 1
- 229960004635 Mesna Drugs 0.000 claims 1
- 229960004857 Mitomycin Drugs 0.000 claims 1
- 229960001156 Mitoxantrone Drugs 0.000 claims 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 229960005163 Netupitant Drugs 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- FBTSQILOGYXGMD-LURJTMIESA-N Nitrotyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C([N+]([O-])=O)=C1 FBTSQILOGYXGMD-LURJTMIESA-N 0.000 claims 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 1
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 1
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 1
- 229950007318 OZOGAMICIN Drugs 0.000 claims 1
- 229960002450 Ofatumumab Drugs 0.000 claims 1
- LZMPYSIUWPEIRA-XFXZXTDPSA-N Ofatumumab Chemical compound N1=C2C=3COCCC=3N=CC2=N\C1=C1\NOC=C1 LZMPYSIUWPEIRA-XFXZXTDPSA-N 0.000 claims 1
- FAQDUNYVKQKNLD-UHFFFAOYSA-N Olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 claims 1
- 206010025310 Other lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 229960001592 Paclitaxel Drugs 0.000 claims 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N Pamidronic acid Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims 1
- FWZRWHZDXBDTFK-ZHACJKMWSA-N Panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 claims 1
- PHXJVRSECIGDHY-UHFFFAOYSA-N Ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 claims 1
- OGSBUKJUDHAQEA-WMCAAGNKSA-N Pralatrexate Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CC(CC#C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OGSBUKJUDHAQEA-WMCAAGNKSA-N 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N Procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N Proprasylyt Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- RWRDJVNMSZYMDV-UHFFFAOYSA-L Radium chloride Chemical compound [Cl-].[Cl-].[Ra+2] RWRDJVNMSZYMDV-UHFFFAOYSA-L 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 108010001645 Rituximab Proteins 0.000 claims 1
- HNMATTJJEPZZMM-BPKVFSPJSA-N S-[(2R,3S,4S,6S)-6-[[(2R,3S,4S,5R,6R)-5-[(2S,4S,5S)-5-[acetyl(ethyl)amino]-4-methoxyoxan-2-yl]oxy-6-[[(2S,5Z,9R,13E)-13-[2-[[4-[(2E)-2-[1-[4-(4-amino-4-oxobutoxy)phenyl]ethylidene]hydrazinyl]-2-methyl-4-oxobutan-2-yl]disulfanyl]ethylidene]-9-hydroxy-12-(m Chemical compound C1[C@H](OC)[C@@H](N(CC)C(C)=O)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@@](C/3=C/CSSC(C)(C)CC(=O)N\N=C(/C)C=3C=CC(OCCCC(N)=O)=CC=3)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HNMATTJJEPZZMM-BPKVFSPJSA-N 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 229940095743 Selective estrogen receptor modulators Drugs 0.000 claims 1
- 206010041823 Squamous cell carcinoma Diseases 0.000 claims 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 claims 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temodal Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N ThioTEPA Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims 1
- 229960005454 Thioguanine Drugs 0.000 claims 1
- 229960001196 Thiotepa Drugs 0.000 claims 1
- 229960002952 Tipiracil Drugs 0.000 claims 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 1
- 108010010691 Trastuzumab Proteins 0.000 claims 1
- 229960001727 Tretinoin Drugs 0.000 claims 1
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 claims 1
- GCPXMJHSNVMWNM-UHFFFAOYSA-N Trihydroxyarsenite(Iii) Chemical compound O[As](O)O GCPXMJHSNVMWNM-UHFFFAOYSA-N 0.000 claims 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N U-18,496 Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 1
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims 1
- 229940045145 Uridine Drugs 0.000 claims 1
- DRTQHJPVMGBUCF-UCVXFZOQSA-N Uridine Natural products O[C@H]1[C@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UCVXFZOQSA-N 0.000 claims 1
- 210000001635 Urinary Tract Anatomy 0.000 claims 1
- XRASPMIURGNCCH-UHFFFAOYSA-N Zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims 1
- MXAYKZJJDUDWDS-LBPRGKRZSA-N [(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]boronic acid Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl MXAYKZJJDUDWDS-LBPRGKRZSA-N 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims 1
- 229960000548 alemtuzumab Drugs 0.000 claims 1
- 229960001445 alitretinoin Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 229960002749 aminolevulinic acid Drugs 0.000 claims 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N aminolevulinic acid Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000003042 antagnostic Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000003972 antineoplastic antibiotic Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 229960001372 aprepitant Drugs 0.000 claims 1
- 239000003886 aromatase inhibitor Substances 0.000 claims 1
- 229960002594 arsenic trioxide Drugs 0.000 claims 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 claims 1
- 108010072668 atezolizumab Proteins 0.000 claims 1
- 229960003852 atezolizumab Drugs 0.000 claims 1
- 229960003005 axitinib Drugs 0.000 claims 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims 1
- 229960002938 bexarotene Drugs 0.000 claims 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 1
- 229960005243 carmustine Drugs 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- ZNEWHQLOPFWXOF-UHFFFAOYSA-N coenzyme M Chemical compound OS(=O)(=O)CCS ZNEWHQLOPFWXOF-UHFFFAOYSA-N 0.000 claims 1
- 229960005061 crizotinib Drugs 0.000 claims 1
- 229960002465 dabrafenib Drugs 0.000 claims 1
- 229960002204 daratumumab Drugs 0.000 claims 1
- 108010031324 daratumumab Proteins 0.000 claims 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229960004497 dinutuximab Drugs 0.000 claims 1
- 108091003638 dinutuximab Proteins 0.000 claims 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 238000005538 encapsulation Methods 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- BQULAXAVRFIAHN-HNCPQSOCSA-N ethyl (2R)-2-amino-3-(4-hydroxyphenyl)propanoate;hydrochloride Chemical compound Cl.CCOC(=O)[C@H](N)CC1=CC=C(O)C=C1 BQULAXAVRFIAHN-HNCPQSOCSA-N 0.000 claims 1
- GITKQXFBNJTMRP-QRPNPIFTSA-N ethyl (2S)-2-amino-3-(4-hydroxy-3-nitrophenyl)propanoate;hydrochloride Chemical compound Cl.CCOC(=O)[C@@H](N)CC1=CC=C(O)C([N+]([O-])=O)=C1 GITKQXFBNJTMRP-QRPNPIFTSA-N 0.000 claims 1
- 229960002074 flutamide Drugs 0.000 claims 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 1
- 235000008191 folinic acid Nutrition 0.000 claims 1
- 239000011672 folinic acid Substances 0.000 claims 1
- 229960002584 gefitinib Drugs 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 229960000578 gemtuzumab Drugs 0.000 claims 1
- 230000014509 gene expression Effects 0.000 claims 1
- 210000004602 germ cell Anatomy 0.000 claims 1
- 229960004859 glucarpidase Drugs 0.000 claims 1
- 108010049491 glucarpidase Proteins 0.000 claims 1
- 229960001330 hydroxycarbamide Drugs 0.000 claims 1
- VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 claims 1
- 229940027318 hydroxyurea Drugs 0.000 claims 1
- 229960001507 ibrutinib Drugs 0.000 claims 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims 1
- 229960002411 imatinib Drugs 0.000 claims 1
- 238000005470 impregnation Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229960005386 ipilimumab Drugs 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- 229960001691 leucovorin Drugs 0.000 claims 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 230000002503 metabolic Effects 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- BICWDWHXTTXTDU-MRVPVSSYSA-N methyl (2R)-2-amino-3-(2,6-dichloro-3,4-dimethoxyphenyl)propanoate Chemical compound COC(=O)[C@H](N)CC1=C(Cl)C=C(OC)C(OC)=C1Cl BICWDWHXTTXTDU-MRVPVSSYSA-N 0.000 claims 1
- BPKBTKQFMPZVNO-SSDOTTSWSA-N methyl (2R)-2-amino-3-(2,6-dichloro-3-hydroxy-4-methoxyphenyl)propanoate Chemical compound COC(=O)[C@H](N)CC1=C(Cl)C=C(OC)C(O)=C1Cl BPKBTKQFMPZVNO-SSDOTTSWSA-N 0.000 claims 1
- ATVDFEWFLSSKBM-MRVPVSSYSA-N methyl (2R)-2-amino-3-(2-chloro-3,4-dimethoxyphenyl)propanoate Chemical compound COC(=O)[C@H](N)CC1=CC=C(OC)C(OC)=C1Cl ATVDFEWFLSSKBM-MRVPVSSYSA-N 0.000 claims 1
- WOOVWLVXVNIALE-SSDOTTSWSA-N methyl (2R)-2-amino-3-(2-chloro-3-hydroxy-4-methoxyphenyl)propanoate Chemical compound COC(=O)[C@H](N)CC1=CC=C(OC)C(O)=C1Cl WOOVWLVXVNIALE-SSDOTTSWSA-N 0.000 claims 1
- URTGFUAPYILQFF-SECBINFHSA-N methyl (2R)-2-amino-3-(2-chloro-4-hydroxyphenyl)propanoate Chemical compound COC(=O)[C@H](N)CC1=CC=C(O)C=C1Cl URTGFUAPYILQFF-SECBINFHSA-N 0.000 claims 1
- JRBGZVHYLIYGFT-SECBINFHSA-N methyl (2R)-2-amino-3-(3-chloro-4,5-dimethoxyphenyl)propanoate Chemical compound COC(=O)[C@H](N)CC1=CC(Cl)=C(OC)C(OC)=C1 JRBGZVHYLIYGFT-SECBINFHSA-N 0.000 claims 1
- KWTIOVPQMRSIJF-MRVPVSSYSA-N methyl (2R)-2-amino-3-(3-chloro-4-hydroxyphenyl)propanoate Chemical compound COC(=O)[C@H](N)CC1=CC=C(O)C(Cl)=C1 KWTIOVPQMRSIJF-MRVPVSSYSA-N 0.000 claims 1
- QUBSTZJVDZUTFR-SECBINFHSA-N methyl (2R)-2-amino-3-(3-chloro-4-methoxyphenyl)propanoate Chemical compound COC(=O)[C@H](N)CC1=CC=C(OC)C(Cl)=C1 QUBSTZJVDZUTFR-SECBINFHSA-N 0.000 claims 1
- ZSDSFDQBWLLWEN-MRVPVSSYSA-N methyl (2R)-2-amino-3-(3-chloro-5-fluoro-4-hydroxyphenyl)propanoate Chemical compound COC(=O)[C@H](N)CC1=CC(F)=C(O)C(Cl)=C1 ZSDSFDQBWLLWEN-MRVPVSSYSA-N 0.000 claims 1
- MWZPENIJLUWBSY-SECBINFHSA-N methyl (2R)-2-amino-3-(4-hydroxyphenyl)propanoate Chemical compound COC(=O)[C@H](N)CC1=CC=C(O)C=C1 MWZPENIJLUWBSY-SECBINFHSA-N 0.000 claims 1
- ZXXAWWHROSUPMV-MRXNPFEDSA-N methyl (2R)-2-amino-3-[4-[(2-chloro-6-fluorophenyl)methoxy]phenyl]propanoate Chemical compound C1=CC(C[C@@H](N)C(=O)OC)=CC=C1OCC1=C(F)C=CC=C1Cl ZXXAWWHROSUPMV-MRXNPFEDSA-N 0.000 claims 1
- 229960000513 necitumumab Drugs 0.000 claims 1
- 108010033813 necitumumab Proteins 0.000 claims 1
- WAXQNWCZJDTGBU-UHFFFAOYSA-N netupitant Chemical compound C=1N=C(N2CCN(C)CC2)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 WAXQNWCZJDTGBU-UHFFFAOYSA-N 0.000 claims 1
- WRFPVMFCRNYQNR-UHFFFAOYSA-N o-Tyrosine Chemical compound OC(=O)C(N)CC1=CC=CC=C1O WRFPVMFCRNYQNR-UHFFFAOYSA-N 0.000 claims 1
- 229960003347 obinutuzumab Drugs 0.000 claims 1
- 108010045555 obinutuzumab Proteins 0.000 claims 1
- 108010052070 ofatumumab Proteins 0.000 claims 1
- 229960000572 olaparib Drugs 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 229940046231 pamidronate Drugs 0.000 claims 1
- 229960005184 panobinostat Drugs 0.000 claims 1
- 229960000639 pazopanib Drugs 0.000 claims 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 229960001131 ponatinib Drugs 0.000 claims 1
- 229960000214 pralatrexate Drugs 0.000 claims 1
- 229960000624 procarbazine Drugs 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 1
- 229960003712 propranolol Drugs 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 229910001630 radium chloride Inorganic materials 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 229930003347 taxol Natural products 0.000 claims 1
- 229960004964 temozolomide Drugs 0.000 claims 1
- 229960000235 temsirolimus Drugs 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000006134 tongue cancer Diseases 0.000 claims 1
- 229960000303 topotecan Drugs 0.000 claims 1
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 claims 1
- 229960002066 vinorelbine Drugs 0.000 claims 1
- 229960004276 zoledronic acid Drugs 0.000 claims 1
Claims (22)
メチル (2R)−2−アミノ−3−(2−クロロ−4−ヒドロキシフェニル)プロパノエート;
D−チロシンエチルエステルヒドロクロリド;
メチル (2R)−2−アミノ−3−(2,6−ジクロロ−3,4−ジメトキシフェニル)プロパノエート;
H−D−Tyr(TBU)−アリルエステルHCl;
メチル (2R)−2−アミノ−3−(3−クロロ−4,5−ジメトキシフェニル)プロパノエート;
メチル (2R)−2−アミノ−3−(2−クロロ−3−ヒドロキシ−4−メトキシフェニル)プロパノエート;
メチル (2R)−2−アミノ−3−(4−[(2−クロロ−6−フルオロフェニル)メトキシ]フェニル)プロパノエート;
メチル (2R)−2−アミノ−3−(2−クロロ−3,4−ジメトキシフェニル)プロパノエート;
メチル (2R)−2−アミノ−3−(3−クロロ−5−フルオロ−4−ヒドロキシフェニル)プロパノエート;
ジエチル 2−(アセチルアミノ)−2−(4−[(2−クロロ−6−フルオロベンジル)オキシ]ベンジルマロネート;
メチル (2R)−2−アミノ−3−(3−クロロ−4−メトキシフェニル)プロパノエート;
メチル (2R)−2−アミノ−3−(3−クロロ−4−ヒドロキシ−5−メトキシエニル)プロパノエート;
メチル (2R)−2−アミノ−3−(2,6−ジクロロ−3−ヒドロキシ−4−メトキシフェニル)プロパノエート;
メチル (2R)−2−アミノ−3−(3−クロロ−4−ヒドロキシフェニル)プロパノエート;
H−DL−tyr−OMe HCl;
H−3,5−ジヨード−tyr−OME HCl;
H−D−3,5−ジヨード−tyr−OME HCl;
H−D−tyr−OMe HCl;
D−チロシンメチルエステルヒドロクロリド;
D−チロシン−OMe HCl;
メチル D−チロシネートヒドロクロリド;
D−チロシンメチルエステルHCl;
H−D−Tyr−OMe−HCl;
(2R)−2−アミノ−3−(4−ヒドロキシフェニル)プロピオン酸;
(2R)−2−アミノ−3−(4−ヒドロキシフェニル)メチルエステルヒドロクロリド;
メチル (2R)−2−アミノ−3−(4−ヒドロキシフェニル)プロパノエートヒドロクロリド;
メチル (2R)−2−アザニル−3−(4−ヒドロキシフェニル)プロパノエートヒドロクロリド;
3−クロロ−L−チロシン;
3−ニトロ−L−チロシン;
3−ニトロ−L−チロシンエチルエステルヒドロクロリド;
DL−m−チロシン;
DL−o−チロシン;
Boc−Tyr(3,5−I2)−OSu;
Fmoc−tyr(3−NO2)−OH;
α−メチル−L−チロシン;
α−メチル−D−チロシン;及び
α−メチル−DL−チロシン
の一つ又は複数である、請求項2に記載の組成物。 Tyrosine derivative
Methyl (2R) -2-amino-3- (2-chloro-4-hydroxyphenyl) propanoate;
D-Tyrosine Ethyl Ester Hydrochloride;
Methyl (2R) -2-amino-3- (2,6-dichloro-3,4-dimethoxyphenyl) propanoate;
HD-Tyr (TBU) -allyl ester HCl;
Methyl (2R) -2-amino-3- (3-chloro-4,5-dimethoxyphenyl) propanoate;
Methyl (2R) -2-amino-3- (2-chloro-3-hydroxy-4-methoxyphenyl) propanoate;
Methyl (2R) -2-amino-3-(4-[(2-chloro-6-fluorophenyl) methoxy] phenyl) propanoate;
Methyl (2R) -2-amino-3- (2-chloro-3,4-dimethoxyphenyl) propanoate;
Methyl (2R) -2-amino-3- (3-chloro-5-fluoro-4-hydroxyphenyl) propanoate;
Diethyl 2- (acetylamino) -2-(4-[(2-chloro-6-fluorobenzyl) oxy] benzylmalonate;
Methyl (2R) -2-amino-3- (3-chloro-4-methoxyphenyl) propanoate;
Methyl (2R) -2-amino-3- (3-chloro-4-hydroxy-5-methoxyenyl) propanoate;
Methyl (2R) -2-amino-3- (2,6-dichloro-3-hydroxy-4-methoxyphenyl) propanoate;
Methyl (2R) -2-amino-3- (3-chloro-4-hydroxyphenyl) propanoate;
HDL-tyr-OMe HCl;
H-3,5-diiodot-tyr-OME HCl;
HD-3,5-diiodot-tyr-OME HCl;
HD-tyr-OMe HCl;
D-tyrosine methyl ester hydrochloride;
D-tyrosine-OMe HCl;
Methyl D-tyrosinate hydrochloride;
D-tyrosine methyl ester HCl;
HD-Tyr-OMe-HCl;
(2R) -2-amino-3- (4-hydroxyphenyl) propionic acid;
(2R) -2-amino-3- (4-hydroxyphenyl) methyl ester hydrochloride;
Methyl (2R) -2-amino-3- (4-hydroxyphenyl) propanoate hydrochloride;
Methyl (2R) -2-azanyl-3- (4-hydroxyphenyl) propanoate hydrochloride;
3-Chloro-L-tyrosine;
3-Nitro-L-Tyrosine;
3-Nitro-L-Tyrosine Ethyl Ester Hydrochloride;
DL-m-tyrosine;
DL-o-tyrosine;
Boc-Tyr (3,5-I 2 ) -OSu;
Fmoc-tyr (3-NO 2 ) -OH;
α-Methyl-L-tyrosine;
The composition according to claim 2, which is one or more of α-methyl-D-tyrosine; and α-methyl-DL-tyrosine.
21. The kit of claim 21, further comprising an additional therapeutic agent.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022122538A JP2022153587A (en) | 2016-11-30 | 2022-08-01 | Tyrosine derivatives and compositions comprising them |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/365,120 | 2016-11-30 | ||
US15/365,120 US20170080093A1 (en) | 2013-10-22 | 2016-11-30 | Tyrosine Derivatives And Compositions Comprising Them |
PCT/US2017/063865 WO2018102506A1 (en) | 2016-11-30 | 2017-11-30 | Tyrosine derivatives and compositions comprising them |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022122538A Division JP2022153587A (en) | 2016-11-30 | 2022-08-01 | Tyrosine derivatives and compositions comprising them |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019536783A JP2019536783A (en) | 2019-12-19 |
JP2019536783A5 true JP2019536783A5 (en) | 2021-01-14 |
Family
ID=60703174
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019528632A Pending JP2019536783A (en) | 2016-11-30 | 2017-11-30 | Tyrosine derivatives and compositions containing them |
JP2022122538A Withdrawn JP2022153587A (en) | 2016-11-30 | 2022-08-01 | Tyrosine derivatives and compositions comprising them |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022122538A Withdrawn JP2022153587A (en) | 2016-11-30 | 2022-08-01 | Tyrosine derivatives and compositions comprising them |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP3548086A1 (en) |
JP (2) | JP2019536783A (en) |
KR (1) | KR20190089191A (en) |
CN (1) | CN110062633A (en) |
AU (1) | AU2017368135A1 (en) |
BR (1) | BR112019011033A2 (en) |
CA (1) | CA3045110A1 (en) |
EA (1) | EA201991305A1 (en) |
IL (1) | IL266840A (en) |
MX (1) | MX2019006326A (en) |
PH (1) | PH12019501186A1 (en) |
WO (1) | WO2018102506A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111743887A (en) * | 2019-03-26 | 2020-10-09 | 深圳先进技术研究院 | Use of alpha-methyl tyrosine or its derivative |
KR20220098682A (en) | 2019-05-14 | 2022-07-12 | 타임, 인크. | Compositions and methods for treating cancer |
CA3167918A1 (en) * | 2020-01-17 | 2021-07-22 | Tyme, Inc. | Compositions and methods for modulating cancer |
US10905698B1 (en) | 2020-05-14 | 2021-02-02 | Tyme, Inc. | Methods of treating SARS-COV-2 infections |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI323662B (en) * | 2002-11-15 | 2010-04-21 | Telik Inc | Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy |
WO2005072061A2 (en) * | 2004-02-02 | 2005-08-11 | Biosight Ltd. | Conjugates for cancer therapy and diagnosis |
CN101516899B (en) * | 2006-04-19 | 2016-07-06 | 得克萨斯大学体系董事会 | The compositions of cell imaging and treatment and method |
US9732055B2 (en) * | 2007-09-10 | 2017-08-15 | Boston Biomedical, Inc. | Compositions and methods for cancer treatment |
CA2862689C (en) * | 2012-01-17 | 2020-03-10 | Tyme, Inc. | .alpha.-methyl-dl-tyrosine, compositions, kits, combinations and use thereof for the treatment of cancer or for reducing cell proliferation |
US9585841B2 (en) | 2013-10-22 | 2017-03-07 | Tyme, Inc. | Tyrosine derivatives and compositions comprising them |
-
2017
- 2017-11-30 KR KR1020197018473A patent/KR20190089191A/en not_active IP Right Cessation
- 2017-11-30 CN CN201780074235.7A patent/CN110062633A/en active Pending
- 2017-11-30 MX MX2019006326A patent/MX2019006326A/en unknown
- 2017-11-30 EP EP17817552.7A patent/EP3548086A1/en active Pending
- 2017-11-30 CA CA3045110A patent/CA3045110A1/en active Pending
- 2017-11-30 BR BR112019011033A patent/BR112019011033A2/en unknown
- 2017-11-30 WO PCT/US2017/063865 patent/WO2018102506A1/en unknown
- 2017-11-30 AU AU2017368135A patent/AU2017368135A1/en not_active Abandoned
- 2017-11-30 EA EA201991305A patent/EA201991305A1/en unknown
- 2017-11-30 JP JP2019528632A patent/JP2019536783A/en active Pending
-
2019
- 2019-05-23 IL IL266840A patent/IL266840A/en unknown
- 2019-05-29 PH PH12019501186A patent/PH12019501186A1/en unknown
-
2022
- 2022-08-01 JP JP2022122538A patent/JP2022153587A/en not_active Withdrawn
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019536783A5 (en) | ||
JP2019501204A5 (en) | ||
JPWO2020130125A1 (en) | Combination of antibody-drug conjugate and kinase inhibitor | |
JP2018533582A5 (en) | ||
JP2019504100A5 (en) | ||
RU2014152107A (en) | COMBINED THERAPY USING CLAUDIN ANTIBODIES 18.2 FOR TREATMENT OF CANCER | |
JP2006265245A5 (en) | ||
RU2014152115A (en) | COMBINED THERAPY USING CLAUDIN ANTIBODIES 18.2 FOR TREATMENT OF CANCER | |
JP2016514103A5 (en) | Complexes containing maytansinoids as cell binding and cytotoxic agents | |
US20220313642A1 (en) | Tyrosine derivatives and compositions comprising them | |
WO2017037292A1 (en) | Combination of a dhodh inhibitor and a her inhibitor for use in the treatment of cancer | |
RU2008141763A (en) | TREATMENT OF BREAST CANCER, NEGATIVE IN THREE RECEPTORS | |
JP2012505838A5 (en) | ||
RU2016127634A (en) | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS FOR APPLICATION AGAINST CANCER AND VIRAL INFECTIONS | |
JP2022153587A (en) | Tyrosine derivatives and compositions comprising them | |
JP2009536956A (en) | Anticancer therapy | |
TW201309298A (en) | Pharmaceutical compositions for treating malignant glioma | |
CN112043831A (en) | Quinolines for use in the combined treatment of breast cancer | |
EP2139469A2 (en) | Cobalamin taxane bioconjugates | |
US11110105B2 (en) | Compounds, composition and uses thereof for treating cancer | |
US20220387544A1 (en) | Novel therapeutic use | |
WO2017151425A1 (en) | Hsp90 inhibitor drug conjugates | |
JP2020535112A (en) | Combination of MIDH1 inhibitor and DNA hypomethylating agent (HMA) | |
KR20140144213A (en) | Novel antitumor agent comprising combination of three agents | |
JPWO2020123991A5 (en) |